Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Merck-and-Company stock
Learn how to easily invest in Merck-and-Company stock.
Merck-and-Company is a drug manufacturers-general business based in the US. Merck-and-Company shares (MRK) are listed on the NYSE and all prices are listed in US Dollars. Merck-and-Company employs 67,000 staff and has a trailing 12-month revenue of around $59 billion.
How to buy Merck-and-Company stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – MRK. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
What's in this guide?
- MRK shares summary
- Compare share dealing platforms
- Is MRK stock a buy or sell?
- Stock performance over time
- Is MRK suitable for ethical investing?
- Are MRK shares over-valued?
- Merck-and-Company's financials
- How volatile are MRK shares?
- Does Merck-and-Company pay a dividend?
- Have MRK shares ever split?
- Other common questions
Merck-and-Company stock price (NYSE: MRK)Use our graph to track the performance of MRK stocks over time.
Merck-and-Company shares at a glance
|Latest market close||$106.09|
|52-week range||$70.61 - $115.49|
|50-day moving average||$108.72|
|200-day moving average||$94.78|
|Wall St. target price||$116.96|
|Dividend yield||$2.72 (2.66%)|
|Earnings per share (TTM)||$6.03|
Buy Merck-and-Company stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Merck-and-Company stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Merck-and-Company price performance over time
|1 week (2023-01-24)||-2.24%|
|1 month (2022-12-30)||-4.38%|
|3 months (2022-10-31)||4.83%|
|6 months (2022-07-29)||18.75%|
|1 year (2022-01-27)||31.66%|
|2 years (2021-01-29)||37.65%|
|3 years (2020-01-31)||24.26%|
|5 years (2018-01-31)||79.05%|
Is Merck-and-Company stock undervalued or overvalued?
Valuing Merck-and-Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Merck-and-Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Merck-and-Company's P/E ratio
Merck-and-Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Merck-and-Company shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Merck-and-Company's PEG ratio
Merck-and-Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.359. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Merck-and-Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Merck-and-Company's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $24.1 billion.
The EBITDA is a measure of a Merck-and-Company's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$59 billion|
|Operating margin TTM||34.51%|
|Gross profit TTM||$35.5 billion|
|Return on assets TTM||12.68%|
|Return on equity TTM||38.15%|
|Market capitalisation||$275.1 billion|
TTM: trailing 12 months
Merck-and-Company's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Merck-and-Company.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Merck-and-Company's total ESG risk score
Total ESG risk: 28.35
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Merck-and-Company's overall score of 28.35 (as at 12/31/2018) is nothing to write home about – landing it in it in the 47th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Merck-and-Company is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Merck-and-Company's environmental score
Environmental score: 3.15/100
Merck-and-Company's environmental score of 3.15 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Merck-and-Company's social score
Social score: 15.55/100
Merck-and-Company's social score of 15.55 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Merck-and-Company is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Merck-and-Company's governance score
Governance score: 12.65/100
Merck-and-Company's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Merck-and-Company is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Merck-and-Company's controversy score
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Merck-and-Company scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Merck-and-Company hasn't always managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
|Total ESG score||28.35|
|Total ESG percentile||47.16|
|Environmental score percentile||4|
|Social score percentile||4|
|Governance score percentile||4|
|Level of controversy||3|
Merck-and-Company share dividends
Dividend payout ratio: 36.55% of net profits
Recently Merck-and-Company has paid out, on average, around 36.55% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.66% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Merck-and-Company shareholders could enjoy a 2.66% return on their shares, in the form of dividend payments. In Merck-and-Company's case, that would currently equate to about $2.72 per share.
While Merck-and-Company's payout ratio might seem fairly standard, it's worth remembering that Merck-and-Company may be investing much of the rest of its net profits in future growth.
Merck-and-Company's most recent dividend payout was on 8 January 2023. The latest dividend was paid out to all shareholders who bought their shares by 13 December 2022 (the "ex-dividend date").
Have Merck-and-Company's shares ever split?
Merck-and-Company's shares were split on a 1048:1000 basis on 2 June 2021. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 1048 shares. This wouldn't directly have changed the overall worth of your Merck-and-Company shares – just the quantity. However, indirectly, the new 4.6% lower share price could have impacted the market appetite for Merck-and-Company shares which in turn could have impacted Merck-and-Company's share price.
Merck-and-Company share price volatility
Over the last 12 months, Merck-and-Company's shares have ranged in value from as little as $70.6102 up to $115.49. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Merck-and-Company's is 0.3931. This would suggest that Merck-and-Company's shares are less volatile than average (for this exchange).
Merck & Co. , Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers.
Merck-and-Company in the news
15 Undervalued Defensive Stocks For 2023
Is Merck & Co. (MRK) a Long-Term Bet?
Merck (NYSE:MRK) Has Announced That It Will Be Increasing Its Dividend To $0.73
Frequently asked questionsWhat percentage of Merck-and-Company is owned by insiders or institutions?
Currently 0.107% of Merck-and-Company shares are held by insiders and 76.481% by institutions. How many people work for Merck-and-Company?
Latest data suggests 67,000 work at Merck-and-Company. When does the fiscal year end for Merck-and-Company?
Merck-and-Company's fiscal year ends in December. Where is Merck-and-Company based?
Merck-and-Company's address is: 2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033 What is Merck-and-Company's ISIN number?
Merck-and-Company's international securities identification number is: US58933Y1055 What is Merck-and-Company's CUSIP number?
Merck-and-Company's Committee on Uniform Securities Identification Procedures number is: 589339209
More guides on Finder
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert